Experimental MDS Drug Appears Beneficial for Some

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Related Keywords

Miami ,Florida ,United States ,Miller School ,Mikkael Sekeres ,University Of Miami Miller School Medicine ,Drug Administration ,International Foundation ,Sylvester Comprehensive Cancer Center ,Division Of Hematology Leukemia Section ,Geron Corporation ,Miami Miller School ,Hematology Leukemia Section ,Aplastic Anemia ,